K. Smart

发表

Differential Amino Acid Uptake into Cerebral Parenchyma and Capillary Cells during Development

J. Preston, H. Al-Sarraf, M. Segal, 1996 .

The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756) − a selective CXCR2 antagonist − in healthy adult subjects

B. Miller, R. Tal-Singer, A. Lazaar, 2015, BMC Pharmacology and Toxicology.

The effects of a TRPV1 antagonist, SB-705498, in the treatment of seasonal allergic rhinitis.

F. Horak, P. Lemell, R. Zieglmayer, 2013, International journal of clinical pharmacology and therapeutics.

The pharmacokinetics of conventional and bioenhanced tablet formulations of danirixin (GSK1325756) following oral administration in healthy, elderly, human volunteers

B. Miller, A. Lazaar, J. Bloomer, 2014, European Journal of Drug Metabolism and Pharmacokinetics.

First-in-Human Phase I Study of Single-agent Vanucizumab, A First-in-Class Bispecific Anti-Angiopoietin-2/Anti-VEGF-A Antibody, in Adult Patients with Advanced Solid Tumors

M. Hidalgo, T. Nayak, K. Stubenrauch, 2017, Clinical Cancer Research.

P152 The Impact of a Selective oral TRPV1 Antagonist in Patients with Chronic Cough

J. Smith, A. Woodcock, A. Kelsall, 2012, Thorax.

PK/PD Mediated Dose Optimization of Emactuzumab, a CSF1R Inhibitor, in Patients With Advanced Solid Tumors and Diffuse‐Type Tenosynovial Giant Cell Tumor

G. Meneses‐Lorente, C. Ries, A. Walz, 2020, Clinical pharmacology and therapeutics.

Hyperammonaemia Reduces Intracellular 22Na (Sodium) Ion and Extracellular 86Rb Ion Concentrations in the Blood-Brain Barrier of the Rat

J. Preston, M. Segal, B. Alexander, 2005, Metabolic Brain Disease.

Transient receptor potential vanilloid 1 (TRPV1) antagonism in patients with refractory chronic cough: a double-blind randomized controlled trial.

J. Smith, A. Woodcock, A. Kelsall, 2014, The Journal of allergy and clinical immunology.

The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756) − a selective CXCR2 antagonist − in healthy adult subjects

B. Miller, R. Tal-Singer, A. Lazaar, 2015, BMC Pharmacology and Toxicology.

The pharmacokinetics of conventional and bioenhanced tablet formulations of danirixin (GSK1325756) following oral administration in healthy, elderly, human volunteers

B. Miller, A. Lazaar, J. Bloomer, 2014, European Journal of Drug Metabolism and Pharmacokinetics.

Inhibition of capsaicin-driven nasal hyper-reactivity by SB-705498, a TRPV1 antagonist.

W. Fokkens, C. V. van Drunen, J. Denyer, 2014, British journal of clinical pharmacology.

TRPV1 inhibition does not prevent cold dry air-elicited symptoms in non-allergic rhinitis.

J. Bentley, J. Denyer, P. Bareille, 2014, International journal of clinical pharmacology and therapeutics.

Efficacy, safety and tolerability of GSK2190915, a 5-lipoxygenase activating protein inhibitor, in adults and adolescents with persistent asthma: a randomised dose-ranging study

N. Snowise, C. Ambery, K. Smart, 2013, Respiratory Research.

Development of a population pharmacokinetic model to characterize the pharmacokinetics of intrathecally administered tominersen in cerebrospinal fluid and plasma

D. Norris, M. Björnsson, Suresh Vatakuti, 2023, CPT: pharmacometrics & systems pharmacology.